GotoPER - Physicians' Education Resource
Back to Home
Free CE/CMEVideo

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Create AccountAlready Registered? Login Here

Release Date

September 30, 2025

Expiration Date

October 1, 2026

Credits

1.0 CME, NCPD

Release Date: September 30, 2025

Expiration Date: September 30, 2026

Activity Overview

This educational activity is an archive of the live presentation held on September 7, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This activity is directed toward WCLC attendees, including an audience of oncologists, radiologists, pulmonologists, oncology RNs/PAs/NPs, and pharmacists involved in the treatment of NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss current and emerging therapeutic options for first- and second-line treatment of EGFR-mutated NSCLC
  • Formulate appropriate strategies for the management of adverse effects related to EGFR targeted therapies in NSCLC
  • Develop individualized treatment plans for patients with EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies
Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

You Also Might Like...

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing CareFree CE/CME

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLCFree CE/CME

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care ModelsLive Event

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New DecisionsFree CE/CME

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Course

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Create Account